TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

28/10/2016 - 2 minutes

Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors.

Adaptimmune logoAdaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, it has entered a collaboration to evaluate its lead candidate NY-ESO SPEAR T-cell therapy in combination with MSD’s Keytruda (pembrolizumab).

Adaptimmune will sponsor the trial aimed at multiple myeloma, a form of blood cancer that affects plasma cells with high rates of relapse. Its  SPEAR technology uses genetically optimized TCRs that recognize the NY-ESO tumor antigen. The therapy already has positive results from Phase I/II in multiple myeloma and also in synovial sarcoma, which Adaptimmune is tackling in collaboration with GSK.

MSD’s Keytruda is an antibody therapy that blocks the checkpoint inhibitor PD-L1, a tumor protein that binds to the PD-1 receptors of T-cells and inhibits the immune response.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!